{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T01:34:23Z","timestamp":1768354463690,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Finnish Psoriasis Assoiation"},{"name":"The Finnish Society for Rheumatology"},{"name":"The Research Committee of the Kuopio University Hospital Catchment Area for the State Research Funding"},{"DOI":"10.13039\/100007753","name":"University of Eastern Finland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007753","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To compare the current disease activity and remission rates, and their regional variation in patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA) in Finland.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data of patients\u2019 most recent visit in 1\/2020\u20139\/2021 were extracted from the Finnish Rheumatology Quality Register. Measures for disease activity and remission included joint counts, DAS28, cDAPSA, CDAI, the Boolean definition, and physician assessment. Regression analyses were applied, adjusted for age and sex.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data of 3598 patients with PsA (51% female, mean age 54\u00a0years) and 13,913 patients with RA (72% female, 74% ACPA-positive, mean age 62\u00a0years) were included. The median (IQR) DAS28 was 1.9 (1.4, 2.6) in PsA and 2.0 (1.6, 2.7) in RA (<jats:italic>p<\/jats:italic>\u2009=\u20090.94); for cDAPSA, the median (IQR) values were 7.7 (3.1, 14) in PsA and 7.7 (3.3, 14) in RA (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). In all regions in both diseases, the median DAS28 was\u2009\u2264\u20092.6 and the median cDAPSA\u2009&lt;\u200913. Remission rates included DAS28\u2009&lt;\u20092.6 in 73% in PsA and 69% in RA (<jats:italic>p<\/jats:italic>\u2009=\u20090.17) and Boolean remission in 17% in PsA and 15% in RA (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). By other definitions of remission, the rates ranged between 30% and 46%. Methotrexate was currently used by 49% in PsA and 57% in RA (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Self-administered bDMARDs were currently used by 37% in PsA and 21% in RA (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The overall disease activity was low and similar in patients with PsA and RA across the country. Remission rates varied between 15 and 73%, depending on the definition but were similar in PsA and RA.\n<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold><jats:italic>\u2022 The disease activity and clinical picture was similar between patients with PsA and RA, in a cross-sectional setting in 1.2020\u20139.2021.<\/jats:italic><jats:italic>\u2022 A significant majority of patients with PsA had low disease activity or were in remission according to cDAPSA. Majority of patients with RA were in remission according to DAS28.<\/jats:italic><jats:italic>\u2022 Patients with PsA and RA used methotrexate similarly. The utilization of bDMARDs was more prevalent in patients with PsA.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-023-06850-y","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T06:01:56Z","timestamp":1703743316000},"page":"633-643","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Similar levels of disease activity and remission rates in patients with psoriatic arthritis and rheumatoid arthritis\u2014results from the Finnish quality register"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5979-7582","authenticated-orcid":false,"given":"Lauri","family":"Weman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"Salo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Kuusalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Huhtakangas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"K\u00e4rki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"V\u00e4h\u00e4salo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Backstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuulikki","family":"Sokka-Isler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"issue":"5","key":"6850_CR1","first-page":"900","volume":"36","author":"E Lubrano","year":"2018","unstructured":"Lubrano E, Mesina F, Caporali R (2018) Clinical remission in rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol 36(5):900\u2013910","journal-title":"Clin Exp Rheumatol"},{"issue":"SUPPL. 2","key":"6850_CR2","first-page":"14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash O (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(SUPPL. 2):14\u201317","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"6850_CR3","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3899\/jrheum.131250","volume":"41","author":"LC Coates","year":"2014","unstructured":"Coates LC, FitzGerald O, Mease PJ, Gladman DD, Strand V, Goel N et al (2014) Development of a disease activity and responder index for psoriatic arthritis - report of the psoriatic arthritis module at OMERACT 11. J Rheumatol 41(4):782\u2013791","journal-title":"J Rheumatol"},{"issue":"8","key":"6850_CR4","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/ard.2009.122259","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS (2010) Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 69(8):1441\u20131447","journal-title":"Ann Rheum Dis"},{"key":"6850_CR5","doi-asserted-by":"crossref","unstructured":"Gon\u00e7alves RSG, De Almeida Martins LM, De Ataide Mariz H, Dantas AT, Duarte ALBP (2020) DAPSA versus cDAPSA: do we need to use CRP? Ann Rheum Dis 79(11):e142","DOI":"10.1136\/annrheumdis-2019-215960"},{"issue":"2","key":"6850_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/annrheumdis-2017-211998","volume":"77","author":"LJJ Van Mens","year":"2018","unstructured":"Van Mens LJJ, Van De Sande MGH, Van Kuijk AWR, Baeten D, Coates LC (2018) Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a reallife cohort. Ann Rheum Dis 77(2):251\u2013257","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"6850_CR7","first-page":"1321","volume":"57","author":"LC Coates","year":"2018","unstructured":"Coates LC, Conaghan PG, D\u2019Agostino MA, De Wit M, FitzGerald O, Kvien TK et al (2018) Remission in psoriatic arthritis-where are we now? Rheumatol (United Kingdom) 57(8):1321\u20131331","journal-title":"Rheumatol (United Kingdom)"},{"issue":"6","key":"6850_CR8","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1093\/rheumatology\/kem051","volume":"46","author":"T Sokka","year":"2007","unstructured":"Sokka T, M\u00e4kinen H, Hannonen P, Pincus T (2007) Most people over age 50 in the general population do not meet ACR remission criteria or OMERACT minimal disease activity criteria for rheumatoid arthritis. Rheumatology 46(6):1020\u20131023","journal-title":"Rheumatology"},{"issue":"1","key":"6850_CR9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/annrheumdis-2013-203860","volume":"73","author":"MM Schoels","year":"2014","unstructured":"Schoels MM, Braun J, Dougados M, Emery P, Fitzgerald O, Kavanaugh A et al (2014) Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis 73(1):238\u2013242","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"6850_CR10","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1002\/art.23794","volume":"58","author":"T Sokka","year":"2008","unstructured":"Sokka T, Hetland ML, M\u00e4kinen H, Kautiainen H, H\u00f8rslev-Petersen K, Luukkainen RK et al (2008) Remission and rheumatoid arthritis data on patients receiving usual care in twenty-four countries. Arthritis Rheum 58(9):2642\u20132651","journal-title":"Arthritis Rheum"},{"issue":"3","key":"6850_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315\u2013324","journal-title":"Arthritis Rheum"},{"key":"6850_CR12","doi-asserted-by":"crossref","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al (2010) 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569\u201381","DOI":"10.1002\/art.27584"},{"issue":"1","key":"6850_CR13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3899\/jrheum.110845","volume":"39","author":"W Tillett","year":"2012","unstructured":"Tillett W, Costa L, Jadon D, Wallis D, Cavill C, McHugh J et al (2012) The ClASsification for Psoriatic ARthritis (CASPAR) criteria - a retrospective feasibility, sensitivity, and specificity study. J Rheumatol 39(1):154\u2013156","journal-title":"J Rheumatol"},{"issue":"5","key":"6850_CR14","first-page":"1877","volume":"61","author":"A Ogdie","year":"2022","unstructured":"Ogdie A, Shin DB, Love TJ, Gelfand JM (2022) Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study. Rheumatol (United Kingdom) 61(5):1877\u20131884","journal-title":"Rheumatol (United Kingdom)"},{"issue":"1","key":"6850_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69(1):48\u201353","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"6850_CR16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Machold K et al (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7(4):796\u2013806","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"6850_CR17","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, Zhang B, Van Tuyl LHD, Funovits J et al (2011) American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70(3):404\u2013413","journal-title":"Ann Rheum Dis"},{"key":"6850_CR18","doi-asserted-by":"crossref","unstructured":"Glintborg B, Jensen DV, Terslev L, Pfeiffer Jensen M, Hendricks O, \u00d8stergaard M et al (2021) Impact of the COVID-19 pandemic on treat-to-target strategies and physical consultations in >7000 patients with inflammatory arthritis. Rheumatol 60(SI):SI3\u2013S12","DOI":"10.1093\/rheumatology\/keab500"},{"issue":"4","key":"6850_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0123582","volume":"10","author":"B Michelsen","year":"2015","unstructured":"Michelsen B, Fiane R, Diamantopoulos AP, Soldal DM, Hansen IJW, Sokka T et al (2015) A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS ONE 10(4):1\u201311","journal-title":"PLoS ONE"},{"issue":"4","key":"6850_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40744-019-00172-9","volume":"6","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Liu M, Rebello S, Kang H, Yi E, Park Y et al (2019) Comparative disease burden in patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis: data from two Corrona registries. Rheumatol Ther 6(4):529\u2013542","journal-title":"Rheumatol Ther"},{"key":"6850_CR21","doi-asserted-by":"crossref","unstructured":"Theander E, Husmark T, Alenius GM, Larsson PT, Teleman A, Geijer M et al (2014) Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis 73(2):407\u2013413","DOI":"10.1136\/annrheumdis-2012-201972"},{"issue":"1","key":"6850_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-016-1151-6","volume":"18","author":"E Nikiphorou","year":"2016","unstructured":"Nikiphorou E, Radner H, Chatzidionysiou K, Desthieux C, Zabalan C, van Eijk-Hustings Y et al (2016) Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Res Ther 18(1):1\u201311","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"6850_CR23","first-page":"1076","volume":"51","author":"M Vermeer","year":"2012","unstructured":"Vermeer M, Kuper HH, van der Bijl AE, Baan H, Posthumus MD, Brus HLM et al (2012) The provisional ACR\/EULAR definition of remission in RA: a comment on the patient global assessment criterion. Rheumatol (United Kingdom) 51(6):1076\u20131080","journal-title":"Rheumatol (United Kingdom)"},{"key":"6850_CR24","doi-asserted-by":"crossref","unstructured":"Ferreira RJ de O, Dougados M, Kirwan JR, Duarte C, de Wit M, Soubrier M et al (2017) Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. Rheumatol (United Kingdom) 56(9):1573\u20131578","DOI":"10.1093\/rheumatology\/kex211"},{"issue":"1","key":"6850_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-07046-1","volume":"12","author":"I Yoshii","year":"2022","unstructured":"Yoshii I, Chijiwa T, Sawada N (2022) Validity and risk of adopting PGA \u2264 2 as a remission criteria of Boolean in clinical practice in patient with rheumatoid arthritis. Sci Rep 12(1):1\u20137","journal-title":"Sci Rep"},{"issue":"9","key":"6850_CR26","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1136\/ard.2005.037903","volume":"64","author":"E Krishnan","year":"2005","unstructured":"Krishnan E, H\u00e4kkinen A, Sokka T, Hannonen P (2005) Impact of age and comorbidities on the criteria for remission and response in rheumatoid arthritis. Ann Rheum Dis 64(9):1350\u20132","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6850_CR27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13075-018-1659-z","volume":"20","author":"G Haugeberg","year":"2018","unstructured":"Haugeberg G, Michelsen B, Tengesdal S, Hansen IJW, Diamantopoulos A, Kavanaugh A (2018) Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. Arthritis Res Ther 20(1):160","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"6850_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13075-015-0716-0","volume":"17","author":"G Haugeberg","year":"2015","unstructured":"Haugeberg G, Hansen IJW, Soldal DM, Sokka T (2015) Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. Arthritis Res Ther 17(1):219","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"6850_CR29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/03009742.2016.1266029","volume":"46","author":"T Rannio","year":"2017","unstructured":"Rannio T, Asikainen J, Hannonen P, Yli-Kerttula T, Ekman P, Piril\u00e4 L et al (2017) Three out of four disease-modifying anti-rheumatic drug-na\u00efve rheumatoid arthritis patients meet 28-joint disease activity score remission at 12 months: results from the FIN-ERA cohort. Scand J Rheumatol 46(6):425\u2013431","journal-title":"Scand J Rheumatol"},{"issue":"00","key":"6850_CR30","first-page":"1","volume":"00","author":"AM Kerola","year":"2022","unstructured":"Kerola AM, Rollefstad S, Kazemi A, Wibetoe G, Sexton J, Mars N et al (2022) Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents. Scand J Rheumatol 00(00):1\u20139","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"6850_CR31","first-page":"37","volume":"37","author":"K Paalanen","year":"2019","unstructured":"Paalanen K, Rannio K, Rannio T, Asikainen J, Hannonen P, Sokka T (2019) Does early seronegative arthritis develop into rheumatoid arthritis? A 10-year observational study. Clin Exp Rheumatol 37(1):37\u201343","journal-title":"Clin Exp Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06850-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06850-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06850-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T11:13:27Z","timestamp":1706786007000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06850-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6850"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06850-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,28]]},"assertion":[{"value":"2 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sokka-Isler: honoraria: Nordic Medicine, Pfizer; research grant: Amgen. Other authors had any conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}